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Abstract
 
Left ventricular (LV) remodeling after myocardial infarction (MI) results in LV dilation, a major
cause of congestive heart failure and sudden cardiac death. Ischemic injury and the ensuing in-
flammatory response participate in LV remodeling, leading to myocardial rupture and LV dila-
tion. Myeloperoxidase (MPO), which accumulates in the infarct zone, is released from neutro-
phils and monocytes leading to the formation of reactive chlorinating species capable of
oxidizing proteins and altering biological function. We studied acute myocardial infarction
(AMI) in a chronic coronary artery ligation model in MPO null mice (MPO
 
 
 
/
 
 
 
). MPO
 
 
 
/
 
 
 
demonstrated decreased leukocyte infiltration, significant reduction in LV dilation, and marked
preservation of LV function. The mechanism appears to be due to decreased oxidative inactiva-
tion of plasminogen activator inhibitor 1 (PAI-1) in the MPO
 
 
 
/
 
 
 
, leading to decreased tissue
plasmin activity. MPO and PAI-1 are shown to have a critical role in the LV response immedi-
ately after MI, as demonstrated by markedly delayed myocardial rupture in the MPO
 
 
 
/
 
  
 
and
accelerated rupture in the PAI-1
 
 
 
/
 
 
 
. These data offer a mechanistic link between inflammation
and LV remodeling by demonstrating a heretofore unrecognized role for MPO and PAI-1 in
orchestrating the myocardial response to AMI.
Key words: myocardial rupture • free radical • chlorination • inﬂammation • protease activation
 
Introduction
 
10% of all individuals over the age of 65 in the United
States have been diagnosed with congestive heart failure,
the vast majority secondary to left ventricular dysfunction,
and LV dilation after acute myocardial infarction (AMI).
The remodeling of the LV after AMI determines myocar-
dial performance and residual left ventricle (LV)
 
*
 
 function.
In the near term (
 
 
 
1 wk) after AMI, the remodeling pro-
cess can lead to myocardial rupture, ventricular septal de-
fect formation, or rupture of a papillary muscle, each of
which, although uncommon, has extremely high mortality
rates. In the long term, remodeling leads to LV dilation, re-
sulting in increased myocardial wall stress and work, ulti-
mately causing decreased functional reserve and congestive
heart failure (1, 2).
The molecular pathways critical to the LV remodeling
process are not yet fully defined. Studies have demonstrated
that mice that are null for the plasminogen activator uroki-
nase (uPA) and matrix metalloprotease-9 have decreased
myocardial rupture (3, 4) and LV dilation (4). However,
the mechanisms responsible for activation of these enzymes
in response to AMI are still under study.
Myeloperoxidase (MPO) is contained in the granules of
neutrophils and monocytes and is released upon leukocyte
activation, resulting in altered biological function of surround-
ing proteins and lipids by the generation of chlorinating,
nitrating, and other oxidizing species (5–8). Leukocytes re-
lease MPO both within the infarct zone after AMI and at
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sites of ventricular rupture (3). To determine whether
MPO-generated oxidants participate in LV rupture and the
remodeling process, we studied AMI in the MPO null
(MPO
 
 
 
/
 
 
 
) mouse (9).
 
Materials and Methods
 
Left Anterior Descending Coronary Artery (LAD) Ligation.
 
All
animal protocols were approved by the Animal Research Com-
mittee and all animals were housed in the American Association
for Accreditation of Laboratory Animal Care–approved animal
facility of the Cleveland Clinic Foundation. Anterior wall myo-
cardial infarction (MI) was induced in 
 
 
 
20–25-g male littermate
WT (C57BL/6J), MPO
 
 
 
/
 
  
 
(9), or plasminogen activator inhibi-
tor 1 (PAI-1)
 
 
 
/
 
  
 
(C57BL/6J background; Jackson ImmunoRe-
search Laboratories; reference 10) mice by ligation of the LAD (3,
4). Animals were intubated and ventilated with room air at 100
breaths per minute using a rodent ventilator (Harvard Apparatus).
Sternotomy was performed and the proximal LAD was identified
using a surgical microscope (Leica M500) after retraction of the
left atrium and ligated with 7-0 prolene. Blanching and dysfunc-
tion of the anterior wall verified LAD ligation. Mice were in-
cluded in survival studies if they were alive the morning after sur-
gery. During our study, we had an 
 
 
 
30% mortality in the WT
and MPO
 
 
 
/
 
  
 
mice, a 40% mortality in the PAI-1
 
 
 
/
 
  
 
mice on the
day of surgery, and a 10% mortality during the first night after
surgery in all groups.
 
Immunohistochemistry.
 
Mice were anesthetized and perfusion
fixed with HistoChoice at physiological pressures. Fixed hearts
were embedded in paraffin and sectioned at 4 
 
 
 
m. Immunohis-
tochemistry for CD45
 
  
 
cells was performed using rat anti–mouse
CD45 antibody and an FITC-labeled rabbit anti–rat IgG second-
ary antibody (Santa Cruz Biotechnology, Inc.).
 
Tissue Processing for Biochemical Analysis.
 
Protein extracts for
biochemical analyses were obtained from tissue from the infarct
zone of hearts that were rapidly perfused with PBS in situ and
frozen in liquid nitrogen. Tissues were minced frozen and ex-
tracts were made in 300 
 
 
 
l buffer containing 10 mM sodium
phosphate, pH 7.2, 150 mM sodium chloride, 1% Triton X-100,
0.1% SDS, 0.5% sodium deoxycholate, and 0.2% sodium azide
for 1 h at 4
 
 
 
C (11, 12) with constant rocking and frequent vor-
texing. Samples were centrifuged at 10,000 rpm and supernatants
were immediately divided into 10-
 
 
 
l aliquots and frozen at
 
 
 
80
 
 
 
C. Protein content was determined using the modified
Lowery method (13). An aliquot was used only once and before
its use, it was diluted with additional extraction buffer to obtain a
final total protein concentration of 5 
 
 
 
g/
 
 
 
l.
 
Collagen Content.
 
Collagen content was determined by picro-
sirius red polarization microscopy for detection of interstitial col-
lagen according to Junqueira’s method (14). We used the proto-
col of Ducharme et al. (4) that has been successfully implemented
in the mouse AMI model. The birefringence under illumination
of myocardium with polarized light identifies collagen, including
types I and III (14). Fresh 5-
 
 
 
M frozen sections of hearts that
were flash frozen after perfusion with PBS from control mice and
mice 12 and 21 d after AMI were fixed in 10% formalin and after
rinsing in distilled water were incubated with 0.1% picrosirius red
F3BA in saturated picric acid for 90 min. Tissues were treated
with 0.01 N HCl for 1 min before being immersed in distilled
water. Tissue sections were then dehydrated, coverslipped, and
imaged under polarized light. Images were captured with the
same exposure time for all tissues and the percent area containing
collagen (yellow birefringence) was determined using NIH Image
software.
 
Echocardiography.
 
2D echocardiography was performed 3–5 d
before AMI as well as on days 3 and 21 after AMI using a 15-
MHz linear array transducer interfaced with a Sequoia C256
(Acuson). Mice were routinely handled to allow for echocardio-
graphy in unsedated mice. We digitally recorded 2D clips and
m-Mode images in a short axis view from the mid-LV just below
the level of the papillary muscles so that we could consistently
obtain measurements from the same anatomical location. Mea-
surements were made off-line using MedArchive Viewer (version
2.1). Each measurement in each animal was made six times from
three randomly chosen m-Mode clips out of five recorded by two
observers blinded to the strain of the mice. As a measure of
LV function, the shortening fraction was calculated from m-Mode
recordings. Shortening fraction (%) 
 
  
 
(LV end diastolic di-
mension [LVEDD]
 
 
 
LV end systolic dimension)/LVEDD
 
*
 
100.
Dimensions were measured between the anterior wall and poste-
rior wall from the short axis view just below the level of the pap-
illary muscle.
 
Zymography.
 
SDS-PAGE was performed under nondenatur-
ing conditions using 10% acrylamide gels impregnated with 1
mg/ml gelatin (as a substrate for matrix metalloproteinase
[MMP]-2 and MMP-9; reference 15) or casein (as a plasmin sub-
strate; reference 16). 10–20 
 
 
 
g protein extract from the infarct
zone was separated over 
 
 
 
2 h at 4
 
 
 
C. Gels were incubated in
2.5% Triton X-100 for 1 h and then in CaCl
 
2 
 
containing solution
overnight at 37
 
 
 
C. Gels were then fixed (methanol/acetic acid
40:10%) and developed with 10% Coomassie blue. Gels were
digitally stored and bands were quantified in arbitrary units using
NIH Image software.
 
Tissue PAI-1 Activity.
 
PAI-1 activity was determined by a
two-stage, indirect enzyme assay system using polylysine-stimu-
lated glu-plasminogen activation (kit 101201; American Diagnos-
tica, Inc.; references 17) or by reverse zymography (18, 19).
 
Two-Stage Indirect Assay for PAI-1.
 
In this assay, 1 U PAI-1
activity is defined as the amount of PAI-1 that inhibits one inter-
national unit of human single chain tissue plasminogen activator
(tPA). In brief, 150 
 
 
 
g total protein extract from the infarct zone
is treated with 40 IU tPA. The reaction mixture is then acidified
to destroy plasmin inhibitors that might be present. PAI-1 activ-
ity was determined by quantifying the residual tPA activity
through the addition of plasminogen and a chromogenic substrate
(Spectrozyme PL; American Diagnostica, Inc.) for plasmin. No
significant signal was obtained if the tPA was not added, suggest-
ing that the level of plasmin activity within the total protein ex-
tract did not contribute to the measured signal. As a control, we
verified that recombinant mouse PAI-1 (Molecular Innovations)
was successfully detected using this system. However, the stan-
dard curve used to determine PAI-1 activity was based on serial
dilutions of tPA.
 
Reverse Zymography for PAI-1.
 
PAI-1 activity was determined
by reverse zymography (18, 19) in SDS-PAGE gel. We separated
20 
 
 
 
g total protein extracts at 4
 
 
 
C on a 12% SDS-PAGE gel con-
taining 1 mg/ml casein, 10 
 
 
 
g/ml human plasminogen (provided
by E. Plow, Cleveland Clinic Foundation, Cleveland, OH) and 0.5
mU/ml human uPA (American Diagnostica, Inc.). Gels were in-
cubated in 2.5% Triton X-100 for 1 h and then in CaCl
 
2 
 
contain-
ing solution overnight at 37
 
 
 
C. Gels were then fixed (water/meth-
anol/acetic 50:40:10%) and developed with 10% Coomassie blue.
Gels were digitally stored and bands were quantified in arbitrary
units using NIH Image software. This protocol was able to detect
the activity of 
 
 
 
1 ng murine PAI-1 (Molecular Innovations).T
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MPO-mediated Oxidation of PAI-1.
 
0.25 
 
 
 
g murine PAI-1
was treated with 25 nM MPO and H
 
2
 
O
 
2 
 
in the presence of 140
mM NaCl, pH 7.4, for 15 min. Treatment with MPO or H
 
2
 
O
 
2
 
alone had no effect on PAI-1 activity. Oxidation was quenched
with 1 mM dithiothreitol for 5 min and then uPA (1 unit; Amer-
ican Diagnostica, Inc.) and CaCl
 
2 
 
(final concentration of 50 
 
 
 
M)
were added to the PAI-1 sample. We assayed the reaction for re-
sidual uPA activity by adding a uPA-specific chromogenic sub-
strate (Spectrozyme UK; American Diagnostica, Inc.) and CaCl
 
2
 
(final concentration of 400 
 
 
 
M). Absorbance was measured at
405 nm as a function of time at 25
 
 
 
C.
 
Quantification of PAI-1 Chlorotyrosine Content.
 
PAI-1 chloro-
tyrosine content was quantified by stable isotope dilution gas chro-
matography-mass spectrometry (7). For in vivo samples, 50 
 
 
 
g
myocardial homogenate at 0, 1, and 3 d after LAD ligation of WT
(
 
n 
 
  
 
4, 7, and 3, respectively) and MPO
 
 
 
/
 
  
 
(
 
n 
 
  
 
4, 4, and 3, re-
spectively) was separated by SDS-PAGE. After transfer to PVDF,
the band corresponding to intact PAI-1 as determined by Western
blot analysis (see below) of adjacent lanes, was cut out and sub-
jected to acid hydrolysis and then mass spectrometry analysis.
 
Western Blot Analysis.
 
A lane from each end of the PVDF was
blocked with 5% milk powder with 0.1% Tween 20. The blots
were incubated in primary antibody to PAI-1 (SC-6644; Santa
Cruz Biotechnology, Inc.) in 5% milk powder with 0.1% Tween
20 for 2 h, washed, and then incubated in secondary antibody in
5% milk powder with 0.1% Tween 20 for 1 h. After washing
three times, the peroxidase was visualized on X-ray film using en-
hanced chemiluminescence.
 
Statistical Analysis.
 
Data are presented as mean 
 
  
 
SD. Com-
parisons between groups were made by Student’s 
 
t 
 
test.
 
Results
 
Effect of MPO on Leukocyte Infiltration after AMI.
 
AMI
of the anterior wall of WT and MPO
 
 
 
/
 
  
 
mice was induced
by chronic ligation of the proximal LAD. WT mice begin
to die from myocardial rupture on day 4 after LAD ligation
in this model (3). Therefore, we initially studied if MPO
had significant effects on the myocardial response to AMI
72 h after LAD ligation. 3 d after AMI, MPO
 
 
 
/
 
  
 
exhibited
preservation of myocardial architecture and significantly
decreased leukocyte infiltration when compared with WT
mice (Figs. 1 and 2). Rather, the infarct zone in the
MPO
 
 
 
/
 
  
 
consists of enucleated (dead) myocytes. Note
there was no significant leukocyte infiltration in the poste-
rior wall, a site remote from the ischemic anterior wall in
either WT or MPO
 
 
 
/
 
  
 
(Fig. 1, C and D).
 
Effect of MPO on LV Remodeling and Function after MI.
 
Cardiac size and function in WT and MPO
 
 
 
/
 
  
 
were mon-
itored by 2D echocardiography after AMI. No significant
differences in cardiac dimensions nor performance were
observed in uninjured WT and MPO
 
 
 
/
 
  
 
mice (Fig. 3, 0
time points). 3 d after AMI, significant thinning of the an-
terior (infarcted) wall was evident in both WT and MPO
 
 
 
/
 
 
 
(Fig. 3 A), without any significant change noted in either
the thickness of the non-infarcted posterior wall (Fig. 3 B)
nor the extent of LVEDD (Fig. 3 C). In contrast, echocar-
diography at 21 d after AMI demonstrated that myocar-
dium from WT possessed significantly thinned anterior
wall with accompanying marked LV chamber dilation,
compared with that observed in the MPO
 
 
 
/
 
  
 
(Fig. 3, A, C,
and D). The differences in dimensions observed at 21 d
were due to an apparent arrest in myocardial thinning and
dilation in the MPO
 
 
 
/
 
  
 
compared with the ongoing LV
remodeling observed in the WT. LV remodeling in the
MPO
 
 
 
/
 
  
 
was accompanied by changes in non-infarct tissue
as evidenced by hypertrophy of the posterior wall in the
MPO
 
 
 
/
 
  
 
at 21 d after AMI (Fig. 3 B).
No significant difference in LV function as measured by
shortening fraction was observed between the non-infarcted
WT and MPO
 
 
 
/
 
  
 
mice nor at 3 d after AMI. However,
Figure 1. Hematoxylin and eosin staining of repre-
sentative cross sections from the mid-ventricle of (A
and C) WT and (B and D) MPO /  3 d after LAD li-
gation. The figures represent (A and B) the infarct zone
and (C and D) the non-infarcted posterior wall. The
insets of A and B show higher power images from the
infarct zone revealing dead enucleated myocytes in the
MPO /  and inflammatory infiltrate in the WT infarct
zones. Bar, 50  M.T
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the combination of decreased LV dilation and posterior wall
hypertrophy resulted in a significant increase ( 85%; Table
I) in LV function at 21 d after AMI in the MPO /  com-
pared with WT.
Role for MPO on Activation of Plasminogen after MI. De-
creased leukocyte infiltration after AMI has been reported
in the uPA /  mouse model (3). Therefore, we postulated
that MPO release after AMI might result in urokinase acti-
vation. The activity of urokinase in the infarct zone after
AMI was determined by quantifying tissue plasmin activity
by zymography. No significant differences in plasmin activ-
ity were observed in uninjured hearts from WT and
MPO /  (not depicted), and baseline plasmin activity was
Figure 2. Quantification of
CD45 immunoreactive cells
within the infarct zone of WT
and MPO /  3 d after LAD liga-
tion (n   6) in each group. Data
represent mean    SD of five
fields per animal.
Figure 3. Echocardiographic analysis of LV size in WT and MPO    as a function of time after AMI. (A) Anterior wall thickness, (B) posterior wall
thickness, and (C) LVEDD before and 3 and 21 d after AMI in WT ( , n   8 at each time point) and MPO    ( , n   8 at 0 and 3 d and n   7 at
21 d after AMI) mice. There were no significant differences in measured parameters 3 d after AMI. At 21 d the anterior and posterior walls were thicker
(P   0.05 and P   0.01, respectively) and the ventricle was less dilated (P   0.01) in the MPO    mice. Data represent mean   SD. (D) Representative
m-mode recording from a WT and MPO    animal 21 d after AMI. *, P   0.05, WT versus MPO   .
Table I. LV Shortening Fraction as a Function of Time after AMI 
in WT and MPO    Mice
Days after AMI WT MPO   
0 58.9   2.0 59.6   3.1
3 25.4   4.8 21.5   2.9
21 12.9   3.1 23.9   4.8a
aP   0.005, MPO versus WT at specified time.
WT, n   8 at each time point.
MPO   , n   8 at 0 and 3 d and n   7 at 21 d.T
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approximately equal to that observed in MPO /  3 d after
LAD ligation (Fig. 4, A and C). There is significantly more
plasmin activity after MI in the WT myocardium. (Fig. 4,
A and C) Of interest, the increase in plasmin activity noted
in WT myocardium was not accompanied by increased
MMP-2 nor MMP-9 activity (Fig. 4, B and D). No signif-
icant MMP-2 nor MMP-9 activities were observed in un-
injured myocardium from WT nor MPO /  (not de-
picted). Quite unexpectedly, our data demonstrate that
both MMP-2 ( 60 kD) and proMMP-9 (94 kD) were sig-
nificantly more up-regulated in the MPO /  3 d after AMI
compared with WT. To verify that the MMP-9 band ob-
served was in fact the pro-form, myocardial extracts were
treated with 4-aminophenylmercuric acetate (20), a chemi-
cal agent that cleaves the proMMP-9 into its active form.
The appropriate shift in electrophoretic mobility was ob-
served, confirming conversion from proMMP-9 to MMP-9
(82 kD; not depicted). We also verified that the bands ob-
served were not secondary to plasmin degradation of gela-
tin by demonstrating that the band identified as MMP-2
and pro/partially active MMP-9 were not sensitive to the
addition of the plasmin inhibitor aprotinin (5  g/ml) to the
CaCl2 reaction solution.
PAI-1 Activity Is Preserved in MPO /  Mice. We postu-
lated that the increase in urokinase activity in the WT myo-
cardium could be due to the decreased activity of its inhib-
itor, PAI-1, because its activity is known to be oxidant
sensitive (21–23). Therefore, we quantified PAI-1 mass and
activity in protein extracts from myocardium of WT and
MPO /  mice using reverse zymography for PAI-1 (Fig. 5,
A and B) and a two-stage plasmin-based PAI-1 activity as-
say (Fig. 5 C). Western blot and activity analyses of PAI-1
in non-infarcted myocardium revealed similar PAI-1 mass
(not depicted) and activity (Fig. 5 B) between the two
stains. Remarkably, 1 d after AMI, PAI-1 activity was sig-
nificantly inhibited in the infarct zone of WT tissue com-
pared with non-infarcted myocardium by  30% as mea-
sured by reverse zymography (Fig. 5 B) and a two-stage
plasmin-based activity assay (Fig. 5 C). However, no signif-
icant inhibition of PAI-1 activity was seen in the myocar-
dial infarct zone of MPO /  mice (Fig. 5, B and C).
Effect of MPO on Myocardial Healing. To determine if
abnormal healing occurred in the MPO    mice, we quan-
tified collagen content in the infarct zone as percent area
containing collagen as a function of time after AMI using
picrosirius red staining (4). Our data demonstrate that there
is no difference in collagen content in control hearts from
WT and MPO /  (Fig. 6). However, at 12 d after AMI,
there is significantly less collagen in the infarct zone of the
MPO    compared with WT. Interestingly, by 21 d after
AMI, the percent area of collagen deposition in the MPO   
is near that of the WT (Fig. 6). This observation is consis-
tent with the increased cellularity of the infarct zone at 21 d
after AMI seen in the MPO /  (not depicted), but not the
plasminogen / , MMP-9 / , nor uPA /  mouse models
(3, 4, 24).
MPO-mediated Oxidation Inhibits PAI-1 Activity. The
above data suggest that in response to AMI, MPO inhibits
PAI-1 activity, leading to increased urokinase activity and
plasmin generation. To test if MPO-generated oxidants can
inhibit PAI-1 activity we used an in vitro PAI-1 assay sys-
tem. PAI-1 activity was quantified by assessing its ability to
inhibit uPA cleavage of chromogenic substrate. Incubation
of PAI-1 with the MPO-H2O2-Cl  system resulted in
Figure 4. Protease activation
within the infarct zone of WT
and MPO   . (A) Representa-
tive casein and (B) gelatin zymo-
grams of protein extracts from
the infarct zones of two repre-
sentative WT and two represen-
tative MPO    mice 3 d after
AMI. Quantification of the den-
sity of (C) plasmin activity band
and the (D) MMP-2 (open bars)
and proMMP-9 (black bars)
bands in the infarct zone of WT
(n     6) and MPO    (n     6)
mice 3 d after AMI. No signifi-
cant differences in plasmin activ-
ity in non-infarct myocardium
between strains were seen, and no
MMP activity was seen in non-
infarcted tissue from either strain.T
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dose-dependent inactivation of PAI-1 (Fig. 7 A) and was
accompanied by increased PAI-1 content of chlorotyrosine
(Fig. 7 B), a specific posttranslational modification of pro-
teins formed by action of MPO-generated oxidation of tar-
get proteins (6, 7). In contrast, incubation of PAI-1 with
either MPO or H2O2 alone had no effect on PAI-1 activity
(not depicted). Thus, MPO-generated oxidants are capable
of inhibiting PAI-1. To determine if MPO promotes oxi-
dative modification of PAI-1 in vivo after AMI, we quanti-
fied the level of chlorotyrosine in PAI-1 recovered from
WT and MPO /  myocardium at baseline, 24 and 72 h af-
ter AMI. PAI-1 was significantly chlorinated in WT mice
24 and 72 h after LAD ligation (Fig. 7 B). In marked con-
trast, no significant chlorotyrosine was detected in PAI-1
recovered from WT nor MPO /  non-infarcted myocar-
dium, nor in myocardium recovered from MPO /  mice
at any time after AMI.
Integral Role for MPO and PAI-1 in Regulating Tissue Deg-
radation after MI. To further demonstrate a critical role for
PAI-1 regulation of the uPA-mediated activation of plas-
min after MI, we performed LAD ligation in PAI-1 / 
mice. Non-infarcted PAI-1 /  demonstrated similar car-
diac function and wall dimensions as WT and MPO / 
(not depicted). 3 d after LAD ligation, the heart of the
PAI-1 /  had significant leukocyte infiltration and areas of
intramyocardial hemorrhage, a feature that was not ob-
served in infarcted myocardium from WT nor MPO / .
To further investigate the importance of MPO effects on
PAI-1 activity after AMI, we studied the survival of WT,
MPO / , and PAI-/1 /  mice as a function of time after
LAD ligation by a surgeon blinded to the identity of the
mice. Death by myocardial rupture was defined by criteria
similar to that used by other investigators (4). The animals
had to (a) be healthy the day before death, (b) have blood
in the cavity at necropsy, and (c) clot on the surface of the
heart, typically at the infarct border zone.
The structural changes in myocardium from MPO / 
mice seen 3 d after LAD ligation were accompanied by a
significant decrease in early myocardial rupture (Fig. 8).
No MPO /  mice died before day 10 after LAD ligation
compared with an overall 40% mortality observed in WT
mice over the same time interval. Long-term (21 d)
MPO /  mice demonstrated similar mortality rates to
WT with a late phase of myocardial rupture beginning on
Figure 5. PAI-1 activity 1 d after AMI in WT and MPO   . (A) Rep-
resentative reverse casein zymograms for PAI-1 activity in protein extracts
from the infarct zones of two representative WT and two MPO    mice
with no MI (filled bars) or one representative MPO   . (B) PAI-1 activ-
ity in WT and MPO /  1 d after AMI (open bars) as quantified in arbi-
trary units from reverse zymograms (n   4 animals per group per time
point). *, P   0.02, WT versus MPO    1 d after AMI. (C) Inhibition of
PAI-1 activity (%) in the infarct zone relative to PAI-1 activity in strain-
matched non-infarcted tissue as measured by two-stage indirect plasmin-
based assay for PAI-1 in WT (n   6) and MPO    (n   6) myocardium 1 d
after LAD ligation. Data represent mean   SD. *, P   0.01.
Figure 6. Collagen content in the infarct zone was quantified as the
percent area that was birefringent under illumination with polarized light
after staining with picrosirius red. Collagen content was quantified from
five areas within the infarct zone from three frozen sections in three ani-
mals per time point in both the WT and MPO   . Data represents mean  
SD. *, P   0.02, WT versus MPO at given time point.T
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day 10 in the MPO /  mice. In stark contrast to the
MPO / , myocardial rupture in the PAI-1 /  was signifi-
cantly accelerated compared with WT, and all PAI-1 / 
mice died of myocardial rupture by day 6 after AMI. Be-
cause patients deficient in PAI-1 have increased bleeding
after surgery (25), we performed sham LAD ligation that
consisted of placement of suture around the LAD without
impeding blood flow. None of these animals died within
the 8 d after surgery. Together, these results support our
hypothesis that MPO-mediated inactivation of PAI-1
plays a significant role in determining the myocardial re-
sponse to AMI.
Discussion
This study provides evidence suggesting a critical role for
MPO and PAI-1 in LV remodeling after MI and offers a
mechanistic link between inflammation and LV dilation af-
ter AMI. In the AMI model of chronic LAD ligation used,
we observed that in MPO /  mice there is decreased leu-
kocyte infiltration, decreased LV dilation, enhanced ven-
tricular function (shortening fraction), and delayed early
death due to myocardial rupture. Decreased leukocyte in-
filtration with preservation of the myocardial structure has
previously been observed in uPA /  and plasminogen / 
mouse models of MI (3, 24). Distinct from the uPA / 
model in which cardiac rupture was completely inhibited
(3), cardiac rupture was markedly delayed in the MPO / .
Despite the decrease in myocardial rupture in the uPA / 
(3) and MMP-9 /  (4) mice, studies using these mice
have described abnormal myocardial healing due to mum-
mification of the dead cardiac myocytes. Failure to clear the
necrotic debris of the infarct zone appears to lead to (a) de-
creased collagen content, (b) increased erythemogenic po-
tential, and (c) decreased responsiveness to inotropic agents
(3, 4). In the MPO /  we observed that myocardial heal-
ing, as quantified by collagen content, is only delayed, not
inhibited, because collagen content in the infarct zone is
similar between the WT and MPO /  at 21 d after AMI.
Given the overall improved LV function at 21 d, this sug-
gests that transient early inhibition of leukocyte recruit-
ment after AMI does not necessitate abnormal healing and
can lead to improved LV remodeling and function.
Leukocyte recruitment in the MPO /  has been shown
to be no different than that in WT mice in a thioglycollate
Figure 7. Effect of MPO-mediated oxidation on PAI-1 activity in
vitro and in vivo. (A) Inhibition of PAI-1 activity as a function of increas-
ing hydrogen peroxide concentration in the presence of 25 nM human
MPO. PAI-1 activity was quantified as residual urokinase activity after in-
cubation with MPO-H2O2-Cl–treated PAI-1. Zero percent PAI-1 inhi-
bition was defined as urokinase activity after incubation with PAI-1
treated with H2O2 or MPO alone and 100% PAI-1 inhibition was defined
as urokinase activity in the absence of PAI-1. Data represent mean   SD
of three samples per H2O2 concentration. (B) Level of protein-bound
3-chlorotyrosine in PAI-1 as measured by gas chromatography-mass
spectrometry after (gray bars) treatment with MPO-H2O2-Cl  at the in-
dicated H2O2 concentrations, or in non-infarcted myocardium or in the
infarct zone of WT (n   7) and MPO    (n   4) 1 and 3 d after LAD li-
gation. Data represent mean   SD.
Figure 8. Survival of WT (solid line, n   17), MPO /  (dotted line,
n   10), and PAI-1 /  (dashed line, n   6) as a function of time after
LAD ligation. No animals died in any group between days 15 and 21.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
622 Effects of MPO Inactivation of PAI on LV Remodeling
peritonitis model (7), suggesting that leukocyte response to
chemotactic factors is preserved in the MPO /  and that
the decreased leukocyte infiltration we observe in the
MPO /  is not due to decreased leukocyte recruitment,
but rather decreased leukocyte entry into the infarct zone.
The mechanism for MPO modulation of leukocyte infiltra-
tion and LV remodeling of the infarct zone appears to be
via activation of the uPA pathway, ultimately leading to in-
creased plasmin generation. Our findings indicate that the
increased plasmin activity in the infarcted myocardium
from the WT mice is due to a decrease in the activity of
the uPA inhibitor, PAI-1. The activity of many members
of the serpin family including PAI-1 (23), but not PAI-2
(26), have been shown to be oxidant sensitive. In this
study, we demonstrated in an in vitro assay system that
PAI-1 activity is sensitive to oxidative inactivation by
MPO-generated oxidants. Moreover, the chlorotyrosine
content of PAI-1 recovered from infarct zone of WT myo-
cardium was in excess of that formed in PAI-1 oxidatively
inactivated by exposure to MPO-generated HOCl, in vitro
(Fig. 7). Thus, MPO-generated oxidants appear to function
as a physiological signal for the inactivation of PAI-1 activ-
ity (Fig. 5, B and C) in the post-AMI setting.
Our observation that the posterior wall hypertrophies in
MPO /  mice in response to acute anterior wall MI might
be a result of the decreased inflammatory response. As seen
in Fig. 1, C and D, there was no significant leukocyte infil-
tration into the posterior wall of WT nor MPO /  3 d
after LAD ligation. Potential mediators of remote LV
dysfunction that are released during the inflammatory
response, such as TNF-  (27), have been shown to have
direct negative inotropic effects on cardiac myocytes as
well as lead to myocardial thinning (28). Thus, in the
MPO / , the posterior wall may hypertrophy due to the
decreased inflammation in the myocardium in response to
the anterior wall ischemia.
The finding that the MPO /  mice had increased ex-
pression of proMMP-9 and MMP-2 was unexpected. The
effect of MPO deficiency on MMP expression in vivo has
not been previously reported. The mechanism for this find-
ing is unknown but may reflect a critical role for MPO in
modulating H2O2 exposure to myocardium in WT mice.
Indeed, H2O2 has been shown to increase MMP expression
in cell culture (29). That MPO /  had increased MMP ex-
pression but exhibited decreased LV dilation after AMI,
suggests that plasmin, and not MMP’s, may have a more
important role in LV remodeling after MI. This concept is
corroborated by the data in the literature that demonstrate
incomplete protection from myocardial rupture after LAD
ligation in MMP-9 null mice but complete protection in
uPA null mice (3, 4). The possibility exists that the in-
creased MMP expression in the MPO /  mice may partic-
ipate in the late phase of myocardial rupture observed in
these animals after AMI.
The ability of PAI-1 to inhibit uPA activity has been
shown to be redox sensitive (21–23). Nonphysiological
models of oxidation such as exposure to caustic oxidants/
chemical agents have documented reduction in PAI-1 ac-
tivity (22). Although the oxidation pathways operational in
vivo have never been examined, a role for oxidative modi-
fication of methionine(s) to methionine sulfoxide during
inactivation of PAI-1 has been suggested (23). HOCl, ma-
jor reactive oxidant formed by the MPO-H2O2-Cl  system
of leukocytes, rapidly scavenges methionine as a primary
target in biological matrices (30).
This study demonstrates that leukocyte-mediated oxida-
tion reactions play a critical role in LV remodeling after
MI. They also identify MPO as an enzymatic participant
in the oxidant-sensitive pathways responsible. Paradoxi-
cally, angiotensin converting enzyme inhibitors (ACE-I)
lower endothelial cell production of PAI-1 (31, 32) as well
as circulating PAI-1 levels (33), and this is one of the pos-
tulated mechanisms by which ACE-I may lead to smaller
infarct size after MI (34). Whether the improved out-
comes in patients on ACE-I with lower circulating PAI-1
levels are due to a decrease in the thrombotic potential of
the vascular wall secondary to increased fibrinolysis or
some PAI-1–independent effect of ACE-I remains to be
determined (35).
It is interesting to note that the current findings may
suggest potential genetic links for the myocardial response
to AMI. MPO levels vary significantly in individuals, are
elevated in subjects with a family history of coronary ar-
tery disease (36), and polymorphisms in the MPO pro-
moter and circulating MPO levels have recently been
shown to be associated with a higher prevalence of coro-
nary artery disease (37).  Similarly, there are multiple
known polymorphisms of PAI-1 such as the 4G/4G geno-
type in the PAI-1 promoter that is associated with in-
creased PAI-1 expression (38). Although the role of PAI-1
and MPO have been intensely studied with respect to the
development and presence of atherosclerosis and plaque
rupture (39–41), the effects of these molecules on LV size
or the development of congestive heart failure after AMI
have not. However, it is intriguing to postulate based on
our data that an interaction of MPO and PAI-1 contrib-
utes to the early myocardial response to AMI. Additional
elucidation of the mechanism of MPO inhibition of PAI-1
may lead to a deeper understanding of the role of the in-
flammatory process on LV remodeling after MI, as well as
identify the molecular targets to augment myocardial per-
formance after cardiac myocyte death.
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